Agios Pharma (AGIO) Tops Q3 EPS by 3c; Reports Cash and Cash Equivalents of $1.4B

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. CSX
7. LRCX
8. LVS
9. SPCX
10. SPY

Go back to Agios Pharma (AGIO) Tops Q3 EPS by 3c; Reports Cash and Cash Equivalents of $1.4B

Agios Reports Business Highlights and Third Quarter 2021 Financial Results

November 3, 2021 7:11 AM EDT

Received FDA Priority Review for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency; PDUFA Date Set for Feb. 17, 2022

Initiated ENERGIZE and ENERGIZE-T Phase 3 Studies in Thalassemia

Agios to Host Investor Day on Nov. 17 to Share Pipeline Updates and Commercial Launch Strategy for Mitapivat in PK Deficiency

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today reported business highlights and financial results for the third quarter ended... More